Replimune (REPL) Income from Non-Controlling Interests (2019 - 2026)
Replimune (REPL) posted Income from Non-Controlling Interests of $510000.0 for Q1 2026, down 0.78% sequentially from $514000.0 in Q4 2025, and down 2.67% YoY from $524000.0 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Replimune has reported Income from Non-Controlling Interests for 8 years, with the latest figure at $510000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 2.67% year-over-year to $510000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $886000.0 (down 59.13% YoY) and the FY2026 annual result came in at $2.1 million, down 2.6% from the prior year.
- Income from Non-Controlling Interests declined to $510000.0 in Q1 2026 per REPL's latest filing, from $514000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $1.2 million in Q3 2024 and troughed at -$458000.0 in Q2 2023.
- A 5-year average of $316000.0 and a median of $514000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2024: Income from Non-Controlling Interests tumbled 510.0% in 2022, then surged 467.76% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at $548000.0 in 2022, then decreased by 1.46% to $540000.0 in 2023, then declined by 2.22% to $528000.0 in 2024, then retreated by 2.65% to $514000.0 in 2025, then fell by 0.78% to $510000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $510000.0, $514000.0, and $131000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 506,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 506,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | 514,000.00 |
| Sep 30, 2025 | 518,000.00 |
| Jun 30, 2025 | 521,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 537,000.00 |
| Dec 31, 2023 | 540,000.00 |
| Sep 30, 2023 | 542,000.00 |
| Jun 30, 2023 | 544,000.00 |
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 548,000.00 |
| Sep 30, 2022 | 550,000.00 |
| Jun 30, 2022 | 552,000.00 |
| Mar 31, 2022 | 553,000.00 |
| Dec 31, 2021 | 555,000.00 |
| Sep 30, 2021 | 557,000.00 |